GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use
GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands the application of Optison to children of all ages, enabling clearer and more accurate echocardiogram imaging.
As one of the only ultrasound agents in the United States without PEG, Optison offers a safer alternative for patients with PEG hypersensitivity. With a proven safety profile and decades of clinical use in adults, this FDA approval follows successful studies demonstrating Optison's efficacy in pediatric heart imaging. GE HealthCare's expanded pediatric indication reflects its commitment to advancing diagnostic tools that improve accuracy while addressing patient safety and comfort, positioning Optison as a vital solution in pediatric cardiology diagnostics.
Shares of the company closed flat at $72.84 yesterday following the announcement. In the year-to-date period, GEHC shares have lost 6.9% against the industry's 5.5% growth. The S&P 500 decreased 0.6% in the same time frame.
The FDA approval of Optison for pediatric use significantly broadens GEHC's market potential by enabling access to a new and critical patient segment. This expansion not only reinforces GEHC's leadership in ultrasound imaging agents but also drives incremental revenue growth through increased adoption in pediatric cardiology. The product is positioned to capture greater market share amid rising demand for advanced, non-invasive diagnostic tools. Over the long term, this approval strengthens GEHC's competitive edge, supports sustained earnings growth, and enhances investor confidence, making the stock poised for upward momentum.
Meanwhile, GEHC currently has a market capitalization of $33.81 billion. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%.
Image Source: Zacks Investment Research
Optison is an advanced ultrasound enhancing agent developed by GEHC, designed to improve the clarity and diagnostic accuracy of echocardiograms. By using gas-filled microbubbles that reflect ultrasound waves more effectively than surrounding tissues or blood, Optison enhances the visibility of the heart chambers and endocardial borders. This improved imaging capability is crucial for cardiologists to assess ventricular function and diagnose heart abnormalities or diseases accurately. Importantly, Optison is the only ultrasound enhancing agent available in the United States that does not contain PEG, a substance known to cause hypersensitivity or anaphylaxis in some patients, making it a safer option for individuals with PEG allergies.
The recent FDA approval for Optison's pediatric indication marks a significant milestone for GEHC. Previously approved for adult use since 1997, Optison's pediatric approval follows a comprehensive Phase IV clinical study that demonstrated its efficacy and safety in children aged 9 to 17. This approval allows cardiologists to extend the use of Optison to pediatric patients with suboptimal echocardiograms, addressing the challenge of obtaining clear heart images in younger patients. The clinical study demonstrated that Optison enhanced the delineation of endocardial borders, improved visualization of left ventricular wall segments, and reduced the number of suboptimal echocardiogram images, thereby facilitating more accurate diagnoses and informed treatment decisions for pediatric heart conditions.
Beyond its diagnostic benefits, Optison's unique safety profile adds considerable value in clinical settings. Unlike many other contrast agents, Optison's PEG-free formulation reduces the risk of hypersensitivity reactions, which is particularly important for vulnerable pediatric patients. Despite its proven safety over decades and use in over 5 million adult patients in the United States, serious adverse reactions remain rare but are closely monitored, with guidelines emphasizing the importance of patient assessment and the availability of resuscitation equipment during administration.
The FDA approval of Optison for pediatric use is set to significantly strengthen GE HealthCare's Pharmaceutical Diagnostics (PDx) segment by expanding its addressable market and driving increased adoption of its ultrasound-enhancing agents. By enabling use in pediatric patients, an important and previously underserved group, Optison can capture new revenue streams and deepen GEHC's footprint in cardiac imaging diagnostics. This approval also enhances the segment's product portfolio with a PEG-free contrast agent, differentiating it from competitors and meeting growing demand for safer, more effective diagnostic tools. Ultimately, this milestone supports PDx's growth trajectory by boosting clinical adoption, improving patient outcomes, and reinforcing GE HealthCare's leadership in innovative diagnostic solutions.
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX.
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
CVS Health has a long-term estimated growth rate of 11.4%. CVS's earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.3%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
CVS Health Corporation (CVS) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
3 hours ago
- Miami Herald
Legendary fund manager sends blunt 6-word message on bitcoin
It's been a wild ride for markets since President Trump announced widespread tariffs on April 2. Trump's so-called "Liberation Day" announcement included higher tariff rates than hoped, leading to investors reworking their expectations for the U.S. economy. There's evidence that a potential U.S. economic slowdown may already be underway, and despite ongoing tariff negotiations, risks remain that tariffs may push the economy into stagflation or outright recession. That risk continues to cast a shadow over risk assets, including stocks and cryptocurrency, which tend to perform best when wallets are fat and consumers and businesses are increasing spending, rather than ratcheting back. Related: President Trump sends harsh message to Federal Reserve on interest rate cuts The stock market sell-off was big, with the S&P 500 and Nasdaq Composite falling 19% and 24% from early-year highs, respectively. Bitcoin fell alongside stocks, losing 27% from its January high through April 8. The drop in risk assets was unsettling, but created opportunity for risk-tolerant investors to 'buy the dip.' Since President Trump paused most of the reciprocal tariffs announced on April 2 on April 9, the Nasdaq and bitcoin have surged higher by 28% and 39% respectively. The gains have been impressive, but not everyone is convinced it will be clear sailing from here. Veteran Wall Street bond manager Bill Gross has navigated good and bad markets since 1971. He co-founded Pacific Investment Management Co., or PIMCO, a huge firm with $2 trillion under management. He formerly managed over $270 billion via PIMCO's Total Return Fund, earning him the "Bond King" nickname before moving to Janus Henderson Investors from 2014 to 2019. Gross offered a blunt message about bitcoin this week, and given his track record, his opinion is worth considering. Image source: Bloomberg/Getty Images There's been considerable debate about what will happen to the economy next. Many think tariffs will tax cash-strapped consumers later this year, lowering economic growth, even as businesses press pause on projects awaiting trade deal clarity. Others believe the risks of tariffs derailing activity are overblown and temporary. The jobs market arguably remains healthy, given that the unemployment rate is relatively low at 4.2%. However, unemployment is up from 3.4% in 2023, and companies announced 93,816 job cuts in May, up 47% year over year, according to Challenger, Grey, & Christmas. Related: Analyst resets stocks, gold outlook after rally The uptick in joblessness prompted the Federal Reserve to cut interest rates by 1% last year; however, the Fed has paused on additional cuts over fear that reducing rates could swell inflation, given that tariffs are only beginning to be felt on prices. The Fed's hesitancy to cut interest rates has drawn sharp criticism from the White House, ostensibly because it recognizes tariffs may slow GDP, worsening unemployment. If the economy were to drop off, and the Fed remained unwilling to budge on interest rates, Congress may be unable to adjust fiscal policy fast enough to bridge the gap, given our deficit and mountain of debt. The U.S. deficit is over $1.8 trillion, representing roughly 6.4% of gross domestic product. Meanwhile, total public debt outstanding is approximately 122% of GDP, far higher than its 75% level in 2008 during the Great Recession. The economic uncertainty has led to bitcoin and gold finding willing buyers as market participants look to diversify risk. Bill Gross's 50 years of Wall Street experience mean he's seen many market pops and drops, including the Nifty 50, skyrocketing inflation in the 1970s, the S&L crisis in the late 80s and early 90s, the Internet boom and bust, the Great Recession, Covid, and the 2002 bear market. More Experts Fed official sends strong message about interest-rate cutsBillionaire fund manager sends surprising message on trade deficitHedge-fund manager sees U.S. becoming Greece In short, Gross has been around the block, making his take on bitcoin worth paying attention to. Gross believes bitcoin is valuable because individuals and others widely hold it, and its supply is capped. "There are now approximately 19.4 million Bitcoins priced at about 107,000 each. The supply of total coins is capped at 21 million over the next few years of "mining," wrote Gross recently on X. "While hard to estimate, approximately 90-95% are held by individuals, institutions, and the moment there is "value" to a Bitcoin." However, Gross appears to think that bitcoin's value may be reflected in its price after its recent rally. "It is in the "meme stock" world for the most part - more valuable than a Trump coin but subject to excessive volatility with underlying value hard to measure," wrote Gross. "There are better risk/reward opportunities," added Gross bluntly. "Any asset category using high leverage is a future risk not only to the asset itself but to the financial system as a whole." Related: Veteran fund manager resets stock market forecast amid Musk, Trump fallout The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
3 hours ago
- Yahoo
FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella
In a June news release, the U.S. Food and Drug Administration revealed that "brown cage-free and brown certified organic eggs" from the August Egg Company have "the potential" to be contaminated with salmonella. The outlet added that the eggs were "sold under multiple different brand names at restaurants and retailers" and should "no longer be available for sale." Those brands are Clover, First Street, Nuaid, O Organics, Marketside, Raleys, Simple Truth, Sun Harvest, and Sunnyside. According to People, over 1.7 million eggs have been recalled in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. On June 6, 2025, the Centers for Disease Control and Prevention revealed they were investigating the "multi-state outbreak of salmonella infections." Mayo Clinic states that while some people with salmonella may have no symptoms, most experience a range of symptoms, like abdominal cramps, within 8 to 72 hours. "In some cases, diarrhea can cause severe dehydration and requires prompt medical attention. Life-threatening complications also may develop if the infection spreads beyond the intestines. The risk of getting salmonella infection is higher with travel to countries without clean drinking water and proper sewage disposal." At this time, 21 people have been hospitalized due to infection, according to the FDA. In a statement, the August Egg Company shared, "We believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes. It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." The company concluded, "We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again."FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella first appeared on Men's Journal on Jun 7, 2025
Yahoo
4 hours ago
- Yahoo
After Hitting All-Time Highs This Year, Is Berkshire Hathaway a Buy Today?
Berkshire Hathaway is run by none other than Warren Buffett, arguably the greatest investor of our time. Berkshire's stock has outperformed the S&P 500 this year and hit all-time highs. Investors seem to like the company's diversity of businesses and its management, and view the stock as a flight to safety. 10 stocks we like better than Berkshire Hathaway › Once the Trump administration began to implement sweeping tariffs against major trading partners of the U.S. in April, investors, sensing a significant disruption in the market, ditched U.S. risk assets and ran for cover. They piled into cash, gold, and assets they believed could provide a port in the storm. One of those happened to be Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), one of the largest conglomerates in the world, run by arguably the world's best investor, Warren Buffett. Berkshire's stock was up nearly 10% (as of June 4), compared to the broader benchmark S&P 500's roughly 2% gain. Berkshire's stock also hit all-time highs earlier this year. Is the stock still a buy today? Aside from Buffett and his strong team of investing lieutenants and managers, one thing investors seem to like about Berkshire is the diversity of businesses under the large conglomerate's umbrella. Berkshire not only operates a massive stock portfolio, but also a large insurance business as the owner of Geico. The company also owns a slate of energy assets, the Burlington North Santa Fe Railroad, and a mortgage business, among others. It might be difficult for some of these sectors to operate alone, but together they provide diversity and have turned Berkshire into a juggernaut that generated over $89.5 billion of earnings in 2024. It also had $47.4 billion of operating earnings, which Buffett believes is a better metric for the company because it strips out volatile unrealized capital gains and losses. Another reason investors view Berkshire as a flight to safety is because of the company's massive cash hoard. Combined, Berkshire's cash, cash equivalents, short-term U.S. Treasury investments, and investments in fixed-maturity securities totaled an incredible $357 billion. Berkshire now reportedly owns about 5% of the short-term Treasury bill market. The massive pile of cash gives Berkshire a huge margin of safety -- and also a war chest, should opportunities arise in the market that Berkshire finds compelling. Now, after a strong run, it's always important to look at a stock's valuation. One way investors like to value Berkshire is on a price-to-tangible book value (TBV) basis, which is a frequent way investors value bank and insurance stocks. As you can see above, Berkshire's stock recently traded slightly under two times TBV. That's down from highs the stock reached earlier this year, but also above the company's five-year average. While Berkshire's stock does look a bit expensive right now, I still think long-term-oriented investors will be served well by owning it. For one, Buffett and his team have built Berkshire to last, meaning it can perform well through the entirety of the economic cycle, including the tougher parts. Berkshire's equities portfolio has exposure to growth stocks like tech and artificial intelligence, but management are also clearly big believers in oil and gas, which they may view as a finite resource. Not only does the company own and operate energy businesses, but Berkshire has major stakes in large domestic oil and gas producers like Occidental Petroleum and Chevron. These stocks should perform well if the price of oil, which trades in the low $60s per barrel, eventually rises. Investors may be concerned over the fact that Buffett, who is 94 years old, is preparing to retire at the end of 2025 after over six decades on the job. No one will ever be able to replace the Oracle of Omaha, but incoming CEO Greg Abel is more than capable. Without the Buffett brand, I think Berkshire may also try to entice investors by returning more capital to shareholders through stock repurchases and perhaps even a dividend, which Berkshire has never paid before. So even with the departure of Buffett, who will stay on as chair of the company's board of directors, it's not all doom and gloom. There is still much more for investors to look forward to. Before you buy stock in Berkshire Hathaway, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Berkshire Hathaway wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway and Chevron. The Motley Fool recommends Occidental Petroleum. The Motley Fool has a disclosure policy. After Hitting All-Time Highs This Year, Is Berkshire Hathaway a Buy Today? was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
